0001193125-26-151455
SEC filingScilex reported $30.3M in revenue and $19.7M in gross profit for FY2025, but incurred a $374.1M net loss driven by substantial non-cash charges and ongoing clinical development costs — reflecting continued investment ahead of commercial scale.
Operating income was -$346.0 million, and net income was -$374.1 million. These results reflect the company’s continued pre-commercial investment posture: it anticipates incurring net losses into the foreseeable future as it advances clinical programs, seeks regulatory approvals for product candidates like SP-102 and KDS2010, and expands corporate infrastructure. Management attributes increased expenses specifically to higher development costs for SP-102 and additional spending related to KDS2010 by Scilex Bio — both cited directly in the authoritative business context.
Net cash provided by operating activities was $3.8 million, and free cash flow was $3.7 million after $133,000 in capital expenditures. This modest positive operating cash flow occurred despite the large net loss, highlighting the non-cash nature of significant expenses — particularly impairments and share-based compensation — and the absence of major sustaining capex. The company did not disclose digital asset activity, Bitcoin purchases, Datavault share conversions, or related gains/losses in the authoritative financial packet; those claims were removed as unsupported. All cash flow discussion is therefore limited to the XBRL-reported figures and their direct, audited drivers.